CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2013--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of the MyTaqTM Blood-PCR Kit, developed for fast,
highly-specific PCR direct from whole blood samples.
Based on the proven MyTaqTM HS DNA polymerase, in combination
with a novel, red-colored, buffer system; the new Bioline MyTaqTM
Blood-PCR Kit overcomes the PCR inhibitors typically present in whole
blood samples in a rapid, easy-to-use protocol.
By using the MyTaqTM Blood-PCR Kit researchers can expect
faster protocols, higher yields and direct gel loading compared to
traditional methods that require complex DNA purification steps and
final sample processing.
Marco Calzavara, President of Bioline commented, "With MyTaqTM
Blood-PCR Kit, researchers can now quickly and easily achieve the purity
and yield necessary for high-performance PCR direct from mammalian blood
samples. This makes MyTaqTM Blood-PCR Kit the perfect
complement to our widely used PCR reagents.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We
are delighted to release the MyTaqTM Blood-PCR Kit which
simplifies the process of PCR extractions from whole blood samples. We
are committed to our life science customers and to bringing innovation
and quality products; such as the MyTaqTM Blood-PCR Kits to
the research laboratory, clinical diagnostic laboratories, and
The MyTaqTM Blood-PCR Kit has been validated with whole blood
samples from a number of mammalian species types and is particularly
suitable for multiplexing, GC rich and longer amplicon applications.
Furthermore, the speed, specificity and simplicity of the MyTaqTM
Blood-PCR Kit makes it ideal for and high-throughput genotyping assays.
For complete information, please visit www.bioline.com/MyTaq.
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
diagnostics manufacturers and biotech companies in more than 60
countries around the world. The Company’s shares are traded on NASDAQ’s
Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com
more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
L. Eberly, email@example.com
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700